Scarica l'app Stockscreener
19.95
0.65%
-0.13
Dopo l'orario di chiusura:
19.95
Precedente Chiudi:
$20.08
Aprire:
$20.23
Volume 24 ore:
1.42M
Relative Volume:
1.36
Capitalizzazione di mercato:
$1.21B
Reddito:
-
Utile/perdita netta:
$-129.61M
Rapporto P/E:
-6.6787
EPS:
-2.9871
Flusso di cassa netto:
$-116.59M
1 W Prestazione:
+1.42%
1M Prestazione:
-9.32%
6M Prestazione:
+24.30%
1 anno Prestazione:
+140.94%
Intervallo 1D:
$19.93
$21.00
Intervallo di 1 settimana:
$19.02
$21.00
Portata 52W:
$6.67
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Nome
Jade Biosciences Inc
Settore
Industria
Telefono
(781) 312-3013
Indirizzo
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
19.95 | 1.22B | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-09 | Iniziato | BTIG Research | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-05-07 | Iniziato | Wedbush | Outperform |
| 2025-05-05 | Iniziato | Stifel | Buy |
| 2025-05-02 | Iniziato | TD Cowen | Buy |
| 2024-06-18 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-06-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-03-25 | Ripresa | Jefferies | Buy |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-12-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-08-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-07-26 | Iniziato | Cowen | Outperform |
| 2021-07-26 | Iniziato | Evercore ISI | Outperform |
| 2021-07-26 | Iniziato | Jefferies | Buy |
| 2021-07-26 | Iniziato | Wedbush | Outperform |
Mostra tutto
Jade Biosciences Inc Borsa (JBIO) Ultime notizie
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences Ord Shs (JBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
JBIO|Jade Biosciences Ord Shs|Price:20.379|Chg%:+0.299 - TradingKey
Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO - TradingView
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ja - GuruFocus
Paradigm Biocapital Advisors LP Acquires Significant Stake in Jade Biosciences Inc - GuruFocus
Jade Biosciences Company Profile & Introduction - Moomoo
Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G - Stock Titan
Jade Biosciences Inc. (JBIO) Climbs 1.67% as Stock Tests Near Resistance at $22.37IV Rank - dars.gov.et
Jade Biosciences Inc. (JBIO) Holds Steady Near Key Resistance as Trading Volume Remains CalmHull Moving Average - DonanımHaber
Price to earnings forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Price to book forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Price to sales forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Enterprise value to EBIT forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Enterprise value to revenue forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Janus Henderson holds 6.27M JBIO shares, reporting 10.6% stake (JBIO) - Stock Titan
JBIOJade Biosciences Inc Options - Finviz
Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - Sahm
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics - Moomoo
JBIO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineRevenue Report - dars.gov.et
Jade BiosciencesParagon Barred From New Ca - Moomoo
Jade Biosciences Secures Exclusive Antibody License Agreement - TipRanks
Jade Biosciences Secures Global Exclusive Antibody License From Paragon Therapeutics With Milestones Up to $22M - TradingView
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
Jade Biosciences (JBIO) Steady Climb: Testing Resistance After Modest GainWedge Breakout - dars.gov.et
Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM:JBIO) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 3000 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 2500 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 3000E Value Benchmark - marketscreener.com
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 2000 Value Benchmark - marketscreener.com
Form 4 Jade Biosciences Inc For: 26 June By Investing.com - Investing.com India
Jade Biosciences (JBIO) director receives 47,675 stock options at $21.81 strike - Stock Titan
Jade Biosciences (JBIO) director Mark Eisner files initial Form 3 - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Jade Biosciences appoints Mark Eisner to board of directors By Investing.com - Investing.com Nigeria
Jade Biosciences appoints Mark Eisner to board of directors - Investing.com
Jade Biosciences Adds Veteran Biopharma Leader to Board - TipRanks
Jade Biosciences Appoints Dr. Mark Eisner to Board, Strengthening Leadership for Autoimmune Therapy Pipeline - Minichart
Jade Biosciences appoints Mark Eisner to its Board and Nominating & Corporate Governance Committee - TradingView
Immunology leader Mark Eisner joins Jade Biosciences (NASDAQ: JBIO) board - Stock Titan
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors - The Manila Times
Jade Biosciences, Inc. Actuals & Estimates (NASDAQ:JBIO) - TradingView
JBIO Forecast — Price Target — Prediction for 2027 - TradingView
Jade Biosciences Inc. (JBIO) Surges 16.77%: Breaking Above Key LevelsPut Dominated - dars.gov.et
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Jade Biosciences (JBIO) Surges 5.6% as Biotech Momentum BuildsAAII Neutral - dars.gov.et
Jade Biosciences Inc Azioni (JBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):